Clinical Study of Electroacupuncture for Postoperative Gastroparesis in Patients With Digestive T… (NCT07546175) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Study of Electroacupuncture for Postoperative Gastroparesis in Patients With Digestive Tract Tumors
76 participantsStarted 2026-04-14
Plain-language summary
This study aims to design and conduct a prospective, multicenter, randomized, parallel-controlled, sham-controlled clinical trial to evaluate the clinical efficacy of electroacupuncture for postsurgical gastroparesis syndrome (PGS) after digestive tract tumor surgery and systematically assess its clinical safety. By measuring gastrointestinal hormones, inflammatory factors, proteomics and metabolomics, we intend to explore the mechanism underlying the improvement of postoperative gastrointestinal motility by electroacupuncture. We will identify the optimal population for electroacupuncture in PGS by analyzing baseline characteristics and efficacy correlations, to provide evidence for individualized clinical intervention. The primary endpoint is the Daily Diary of Gastroparesis Cardinal Symptom Index (GCSI-DD) score at Day 14 of treatment. Finally, based on clinical data, this study will define the eligible population and optimal protocol of electroacupuncture for PGS, and further standardize and promote its clinical application in postoperative complications of cancer.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18-65 years;
✓. History of digestive system tumor surgery;
✓. Meet the diagnostic criteria for PGS (postoperative gastroparesis syndrome);
✓. Voluntarily sign the informed consent form
Exclusion criteria
✕. Gastroparesis caused by other diseases, such as diabetes mellitus or scleroderma;
✕. Use of medications that affect gastric smooth muscle function, such as morphine or atropine;
✕. Suspected or confirmed history of alcohol addiction or drug abuse, or concomitant cognitive impairment or severe mental illness that precludes cooperation with the clinical study;
✕. Severe organic diseases of vital organs, such as severe chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary fibrosis, or complicated by respiratory failure; renal insufficiency or glomerulosclerosis; or severe disturbances of fluid, electrolyte, or acid-base balance;
✕
What they're measuring
1
Daily Diary of Gastroparesis Cardinal Symptom Index (GCSI-DD) score
Timeframe: Assessment time points include before treatment, on day 7 and day 14 of treatment, as well as follow-ups on days 7, 14, 21, and 28 after treatment.
Trial details
NCT IDNCT07546175
SponsorFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine